SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Spero Therapeutics Q3 net loss widens on SP001 licensing payment

Spero Therapeutics Q3 net loss widens on SP001 licensing payment Overview US biopharma firm's Q3 rev

ALTCLRBLQDASPRO

Related stories